Associated organisationsUniversity of Edinburgh · University of NottinghamEurope PMC affiliations are not treated as award recipients or mapped locations.
Funding£3.0M
PeriodMar 2024 — Sept 2028
In plain English
AI plain-English summary
Most transplanted islets—the insulin-producing cells that could cure Type 1 diabetes—are destroyed within days by inflammation and immune attack, even when the procedure works. Researchers have developed biodegradable microparticles, smaller than a grain of salt, that carry anti-inflammatory and pro-regenerative drugs directly to the liver, where islets are implanted. In diabetic mice, a single dose of these drug-loaded particles—at a fraction of the systemic dose—significantly improved blood sugar control. This matters because islet transplantation currently rarely achieves long-term insulin independence. The immune system and inflammation kill most transplanted cells, forcing patients to remain on insulin. The particles are made from a polymer already approved for use in human pharmaceuticals, and they target the liver specifically via a sugar molecule that binds to a receptor found only on liver cells. If this approach works in human trials, it could transform islet transplantation from a temporary stabilisation procedure into a reliable, long-term treatment that frees people with Type 1 diabetes from daily insulin injections. The team will test the particles in large animal models and on human liver tissue, then work with a regulatory body to prepare for clinical use.
View original technical description
Islet transplantation into the liver of someone with Type 1 diabetes stabilises blood glucose control but rarely results in insulin independence, as most islets are destroyed post-transplant from inflammation and immune-mediated mechanisms. We have developed microparticles (MPs) from the polymer poly(DL-lactic-co-glycolic acid): a biodegradable material used in pharmaceutical formulations in which drugs can be loaded and their release controlled. The polymer has a galactose (Gal) moiety attached to it and targets the liver via the liver-specific asialoglycoprotein receptor (ASGPR). We have determined the safe and effective dose of specific anti-inflammatory and pro-regenerative drugs which significantly improves glycaemic control in a diabetic mouse model transplanted with islets via the portal vein. Importantly, the effective dose of drugs is a fraction of the systemic dose required. Our objectives are to : 1. Develop a range of Gal-MPs packaged individually with anti-inflammatory/immunomodulatory and pro-regenerative drugs (Drug-Gal-MPs) to target the liver with appropriate release kinetics; 2. Demonstrate efficacy/safety/mechanism of action of islets co-transplanted with these Drug-Gal-MPs including Drug-MPs in combination; 3. Understand regulatory landscape. We will assess the: 1. Release kinetics of other Drug-Gal-MPs already developed; 2. Biodistribution /pharmacokinetics of Drug-Gal-MPs; 3. Short-term effects of Gal-MPs on liver; 4. Long-term metabolic effects of Gal-MPs. We will develop the most efficacious Drug-Gal-MPs to GLP-grade, test in small and large animal models with islets including ex-vivo in human liver. We will explore the Drug-Gal-MPs with hESC islets through our collaborators and work with Catapult to understand the regulatory landscape to develop the Drug-Gal-MPs for clinical use.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know